Liminatus Pharma, Inc. (LIMN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US53271X1081
Liminatus Pharma, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -3.33 m USD | -2.97 m USD |
| EBIT | -3.33 m USD | -10.07 m USD |
| Net income | -3.55 m USD | -10.21 m USD |
| Diluted EPS – continuing operations | -0.20 USD | -0.43 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
More stocks
- TaoWeave, Inc. (TWAV)
- Knightscope, Inc. (KSCP)
- CYANOTECH CORP (CYAN)
- Twin Vee PowerCats, Co. (VEEE)
- Aclarion, Inc. (ACON)
- Traws Pharma, Inc. (TRAW)
- OLB GROUP, INC. (OLB)
- SUIC Worldwide Holdings Ltd. (SUIC)
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
- Perfect Moment Ltd. (PMNT)
- Global Innovative Platforms Inc. (GIPL)
- GHST World Inc. (GHST)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.